Biomerica INC 8-K filings

Biomerica, Inc. has entered into a definitive agreement to sell its 6% equity interest in Polish medical firm Diagnosis S.A. to affiliates of its CEO for $500,000.

Biomerica, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the re-election of directors, executive compensation, auditor ratification, an increase in the stock incentive plan, and a significant increase in authorized common stock.

Biomerica, Inc. announced the appointment of Gary Huff, former CEO of LabCorp Diagnostics, as an independent director, while Dr. Jane Emerson will not seek re-election.

Biomerica, Inc. announced the appointment of Eric B. Chin, a seasoned financial executive, to its Board of Directors and as Chairperson of the Audit Committee, following the resignation of Ms. Cathy Coste.

Biomerica, Inc. will implement a 1-for-8 reverse stock split, effective April 21, 2025, to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement.

Biomerica's 2024 Annual Meeting saw stockholders approve the election of board members, executive compensation, a new stock incentive plan, and potential amendments for a reverse stock split and increased authorized shares.

Biomerica has received an extension from Nasdaq until May 5, 2025, to regain compliance with the minimum bid price requirement for its common stock.

Biomerica's Chairman of the Board, Jack Kenny, has resigned from his position, effective immediately, with no indication of disagreement with the company.

Biomerica has entered into an agreement to sell up to $5.5 million of its common stock through an at-the-market offering and received a notice from Nasdaq regarding non-compliance with minimum bid price requirements.